Antimalarial medication multi-drug resistant "P. falciparum". It is a very potent blood schizonticide with a long half-life. It is thought to act by forming toxic heme complexes that damage parasitic food vacuoles. Mefloquine is effective in prophylaxis and for acute therapy. It is now used solely for the prevention of resistant strains of "P. falciparum" (usually combined with Artesunate) despite being effective against "P. vivax", "P. ovale" and "P. marlariae". Chloroquine/proguanil or sulfa drug-pyrimethamine combinations should be used in all other plasmodia infections. The major commercial manufacturer of mefloquine-based malaria treatment is Roche Pharmaceuticals, which markets the drug under the trade name
Association for the Treatment of Sexual Abusers Association for the Treatment of Sexual Abusers The Association for the Treatment of Sexual Abusers (ATSA) is an international, multi-disciplinary, non-profit organization dedicated to making society safer by preventing sexual abuse. ATSA promotes sound research, evidence-based practice, informed public policy, and collaborative community strategies that lead to the effective assessment, treatment, and management of individuals who sexually abuse or are at risk to abuse. ATSA sets ethical and practice standards for treatment providers, and provides referrals. The association was incorporated in 1985 and has its headquarters in Beaverton, Oregon, United States. ATSA is an international organization focused on the prevention